Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation
Joseph M. Rocco, Christina Mallarino-Haeger, Attiya Randolph, Susan M. Ray, Marcos C. Schechter, Christa S. Zerbe, Steven M. Holland, Irini Sereti
Abstract
The development of effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines has been a significant accomplishment. Adverse events are extremely rare, but continued surveillance is important, especially in at-risk populations. In 5 patients with preexisting immune dysregulation, hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis, developed after SARS-CoV-2 mRNA vaccination. Early recognition of this rare condition is essential.
Topics & Concepts
MedicineVaccinationImmunologyImmune systemImmune dysregulationCoronavirusCoronavirus disease 2019 (COVID-19)Internal medicineDiseaseInfectious disease (medical specialty)Autoimmune and Inflammatory Disorders ResearchImmune Cell Function and InteractionParvovirus B19 Infection Studies